{"id":"W2996433778","doi":"10.1016/j.ejca.2019.11.006","title":"Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer","year":2019,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Osimertinib; Gefitinib; Medicine; Erlotinib; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Post-hoc analysis; Oncology; Discontinuation; Clinical endpoint; Performance status; Clinical trial; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003883561,0.0004699382,0.001223076,0.0003984873,0.0002633099,0.0007403458,0.0004073108,0.0006095143,0.002597013],"category_scores_gemma":[0.002970016,0.000127772,0.002616226,0.0003954557,0.0004293543,0.0005553368,0.0004935674,0.001100689,0.0001998781],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006655066,"about_ca_system_score_gemma":0.0004985539,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006905224,"about_ca_topic_score_gemma":0.001560243,"domain_scores_codex":[0.9984512,0.0008592108,0.0001531812,0.0001732007,0.0001938246,0.0001693302],"domain_scores_gemma":[0.9976009,0.0008183953,0.0009345927,0.00006716636,0.00008862146,0.0004903876],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7485017,0.005464437,0.1024637,0.001935838,0.008347412,0.0001555043,0.0003385463,0.003970158,0.003531788,0.0002495766,0.002140033,0.1229014],"study_design_scores_gemma":[0.128136,0.3651825,0.4849592,0.0003137742,0.007970299,0.0005440245,0.0003343296,0.006731241,0.002409973,0.0006040967,0.002696624,0.0001180255],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953161,0.002803774,0.0001127881,0.0001905143,0.00005024131,0.0001146149,0.0005436325,0.00001285247,0.00085565],"genre_scores_gemma":[0.9987281,0.000306715,0.0001048262,0.0001194652,0.00005605659,0.00009650285,0.0003936305,0.000001616265,0.0001929738],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003883561,"threshold_uncertainty_score":0.02053845,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01277167070734162,"score_gpt":0.2964873808127632,"score_spread":0.2837157101054215,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}